277 related articles for article (PubMed ID: 26012253)
81. Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms.
Court MH; Duan SX; von Moltke LL; Greenblatt DJ; Patten CJ; Miners JO; Mackenzie PI
J Pharmacol Exp Ther; 2001 Dec; 299(3):998-1006. PubMed ID: 11714888
[TBL] [Abstract][Full Text] [Related]
82. Inhibition of UDP-glucuronosyltransferases (UGTs) by phthalate monoesters.
Du Z; Cao YF; Li SN; Hu CM; Fu ZW; Huang CT; Sun XY; Liu YZ; Yang K; Fang ZZ
Chemosphere; 2018 Apr; 197():7-13. PubMed ID: 29328989
[TBL] [Abstract][Full Text] [Related]
83. Comparison of the inhibition capability of oleanolic acid and betulinic acid towards drug-metabolizing enzymes.
Xiao W; Lu MH
Afr Health Sci; 2015 Sep; 15(3):1011-5. PubMed ID: 26957994
[TBL] [Abstract][Full Text] [Related]
84. Warfarin is an effective modifier of multiple UDP-glucuronosyltransferase enzymes: evaluation of its potential to alter the pharmacokinetics of zidovudine.
Sun H; Zhang T; Wu Z; Wu B
J Pharm Sci; 2015 Jan; 104(1):244-56. PubMed ID: 25393417
[TBL] [Abstract][Full Text] [Related]
85. Morphine glucuronidation and glucosidation represent complementary metabolic pathways that are both catalyzed by UDP-glucuronosyltransferase 2B7: kinetic, inhibition, and molecular modeling studies.
Chau N; Elliot DJ; Lewis BC; Burns K; Johnston MR; Mackenzie PI; Miners JO
J Pharmacol Exp Ther; 2014 Apr; 349(1):126-37. PubMed ID: 24459244
[TBL] [Abstract][Full Text] [Related]
86. A model of in vitro UDP-glucuronosyltransferase inhibition by bile acids predicts possible metabolic disorders.
Fang ZZ; He RR; Cao YF; Tanaka N; Jiang C; Krausz KW; Qi Y; Dong PP; Ai CZ; Sun XY; Hong M; Ge GB; Gonzalez FJ; Ma XC; Sun HZ
J Lipid Res; 2013 Dec; 54(12):3334-44. PubMed ID: 24115227
[TBL] [Abstract][Full Text] [Related]
87. Characterization of hepatic and intestinal glucuronidation of magnolol: application of the relative activity factor approach to decipher the contributions of multiple UDP-glucuronosyltransferase isoforms.
Zhu L; Ge G; Zhang H; Liu H; He G; Liang S; Zhang Y; Fang Z; Dong P; Finel M; Yang L
Drug Metab Dispos; 2012 Mar; 40(3):529-38. PubMed ID: 22180045
[TBL] [Abstract][Full Text] [Related]
88. Identification of human UDP-glucuronosyltransferases involved in N-carbamoyl glucuronidation of lorcaserin.
Sadeque AJ; Usmani KA; Palamar S; Cerny MA; Chen WG
Drug Metab Dispos; 2012 Apr; 40(4):772-8. PubMed ID: 22259019
[TBL] [Abstract][Full Text] [Related]
89. The inhibition study of human UDP-glucuronosyltransferases with cytochrome P450 selective substrates and inhibitors.
Liu Y; She M; Wu Z; Dai R
J Enzyme Inhib Med Chem; 2011 Jun; 26(3):386-93. PubMed ID: 20939765
[TBL] [Abstract][Full Text] [Related]
90. Metabolism of kurarinone by human liver microsomes and its effect on cytotoxicity.
Zhang X; Jiang P; Chen P; Cheng N
Pharm Biol; 2016; 54(4):619-27. PubMed ID: 26429409
[TBL] [Abstract][Full Text] [Related]
91. UDP-glucuronosyltransferase (UGT) 1A1 mainly contributes to the glucuronidation of trovafloxacin.
Fujiwara R; Sumida K; Kutsuno Y; Sakamoto M; Itoh T
Drug Metab Pharmacokinet; 2015 Feb; 30(1):82-8. PubMed ID: 25760534
[TBL] [Abstract][Full Text] [Related]
92. Interactions between human UGT1A1, UGT1A4, and UGT1A6 affect their enzymatic activities.
Fujiwara R; Nakajima M; Yamanaka H; Katoh M; Yokoi T
Drug Metab Dispos; 2007 Oct; 35(10):1781-7. PubMed ID: 17620344
[TBL] [Abstract][Full Text] [Related]
93. Species differences in inhibition potential of nonsteroidal anti-inflammatory drugs against estradiol 3beta-glucuronidation between rats, dogs, and humans.
Mano Y; Usui T; Kamimura H
J Pharm Sci; 2008 Jul; 97(7):2805-10. PubMed ID: 17763456
[TBL] [Abstract][Full Text] [Related]
94. 4-Aminobiphenyl N-glucuronidation by liver microsomes: optimization of the reaction conditions and characterization of the UDP-glucuronosyltransferase isoforms.
Al-Zoughool M; Talaska G
J Appl Toxicol; 2006; 26(6):524-32. PubMed ID: 17080401
[TBL] [Abstract][Full Text] [Related]
95. Acyl glucuronidation of fluoroquinolone antibiotics by the UDP-glucuronosyltransferase 1A subfamily in human liver microsomes.
Tachibana M; Tanaka M; Masubuchi Y; Horie T
Drug Metab Dispos; 2005 Jun; 33(6):803-11. PubMed ID: 15769885
[TBL] [Abstract][Full Text] [Related]
96. Cabozantinib Carries the Risk of Drug-Drug Interactions
Wang Z; Jiang L; Wang X; Yin H; Wang Z; Lv X; Liu Y
Curr Drug Metab; 2022; 23(11):912-919. PubMed ID: 36306450
[TBL] [Abstract][Full Text] [Related]
97. Effect of efavirenz on UDP-glucuronosyltransferase 1A1, 1A4, 1A6, and 1A9 activities in human liver microsomes.
Ji HY; Lee H; Lim SR; Kim JH; Lee HS
Molecules; 2012 Jan; 17(1):851-60. PubMed ID: 22252501
[TBL] [Abstract][Full Text] [Related]
98. The small-molecule tyrosine kinase inhibitor nilotinib is a potent noncompetitive inhibitor of the SN-38 glucuronidation by human UGT1A1.
Fujita K; Sugiyama M; Akiyama Y; Ando Y; Sasaki Y
Cancer Chemother Pharmacol; 2011 Jan; 67(1):237-41. PubMed ID: 20814789
[TBL] [Abstract][Full Text] [Related]
99. Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes.
Kuehl GE; Lampe JW; Potter JD; Bigler J
Drug Metab Dispos; 2005 Jul; 33(7):1027-35. PubMed ID: 15843492
[TBL] [Abstract][Full Text] [Related]
100. Inhibitory effects of commonly used herbal extracts on UDP-glucuronosyltransferase 1A4, 1A6, and 1A9 enzyme activities.
Mohamed ME; Frye RF
Drug Metab Dispos; 2011 Sep; 39(9):1522-8. PubMed ID: 21632963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
